Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BTX-7312 |
| Synonyms | |
| Therapy Description |
BTX-7312 is a bifunctional SOS1 degrader that potentially decreases downstream KRAS signaling and inhibits tumor growth (PMID: 38224565). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BTX-7312 | BTX7312|BTX 7312 | SOS1 Inhibitor 17 | BTX-7312 is a bifunctional SOS1 degrader that potentially decreases downstream KRAS signaling and inhibits tumor growth (PMID: 38224565). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| HRAS Q61H | uterine cancer | sensitive | BTX-7312 | Preclinical - Cell culture | Actionable | In a preclinical study, BTX-7312 inhibited proliferation of a uterine cancer cell line harboring HRAS Q61H in 3D culture (PMID: 38224565). | 38224565 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|